Eli Lilly’s weight loss and diabetes drug tops Keytruda
Digest more
The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a ...
Eli Lilly’s stock rallies, as Zepbound sales nearly tripled, leading to record revenue and a raised full-year outlook.
Eli Lilly stock (NYSE: LLY) is up 7% in a month, warranting investor attention following a key corporate development. Eli ...
In parallel with mazisotine’s shelving, Lilly added a phase 1 NaV1.8 inhibitor from its SiteOne Therapeutics acquisition to ...
The Big Pharma mainstay blew away EPS and revenue expectations when it reported Q3 financials, with management raising ...
Eli Lilly reported higher profit and raised its outlook on surging demand for its weight-loss drugs, sending its shares ...
Eli Lilly and Company and Walmart have announced a partnership to offer Zepbound single-dose vials at Walmart pharmacies. The ...
Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.
Revenue from Mounjaro, the company’s Type 2 diabetes treatment, came in at $6.5 billion, above analysts’ consensus estimate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback